Suresnes (France), June 12th, 2025 – Servier, an independent international pharmaceutical company governed by a non-profit foundation, ranks for the first time 1st worldwide pharma working with patients’ groups in the 2024 PatientView annual Corporate Reputation, Cancer Edition. Based on the feedback from 550 patient groups, this recognition celebrates the Group’s strong commitment to patient collaboration, from involving patient communities in early projects to building transparent, and long-term dialogue.
In this year’s survey, Servier ranks 1st in different categories among which Patient centricity, data transparency, long-term relationship, development of products of benefits and R&D engagement.
The Group also ranks 2nd out of 32 companies in the PatientView survey conducted among patient organizations declaring to “know the company”.
“Our distinctive governance model enables us to remain truly patient-centric in all our actions and these results reflect this commitment to placing the patient voice at the heart of everything we do. As a leader in the field of rare cancers, we have a responsibility to address the real challenges patients face by providing meaningful, personalized solutions. I would like to express my heartfelt thanks to the patient organizations for the trust they continue to place in us.”
Arnaud Lallouette, Executive Vice President Global Medical & Patient Affairs, Servier
This year, Servier also entered the top 10 (8th) in the PatientView global ranking measuring the reputation of 45 companies working with patients’ groups across all therapeutic areas. Thanks to our significant growth over the past few years, Servier has been qualified “Fastest Riser”, which means that it is among the companies rising the most in the upper rankings. This outcome is additional proof of Servier’s overall commitment to innovation in this field for and with patients worldwide, underlining our relentless efforts to put patients at the heart of our work.
Figures to remember
place: patient groups working with Servier (out of 28 pharmaceutical companies) – oncology
place: patient groups familiar with Servier (out of 32 pharmaceutical companies) – oncology
place: patient groups working with Servier (out of 46 companies) – across all therapeutic areas
NRD24-INST-ADV-025 08/2025
